logo

Training Centers

We are proud to partner with several leading cardiovascular centers across the United States to educate interventionalists on the clinical applications and value of robotic PCI. Training centers include:

newyork

Course Proctors

paul

Dr. Paul T. Campbell is an interventional cardiologist with the Sanger Heart & Vascular Institute. He has more than 25 years of experience in the field at the Carolinas Healthcare System NorthEast (CHS-NE). His main research interests are robotics in cardiovascular interventions and radiation safety in the cath lab. He trained in medicine and cardiology at Duke University and he is a member of the Duke University Cooperative Cardiovascular Society. He is a fellow of The Society for Cardiovascular Angiography and Interventions and the American College of Cardiology.

The Sanger Heart & Vascular Institute, part of Carolinas Healthcare System, encompasses more than 175 providers and 20 Care Centers across the Carolinas. Carolinas HealthCare System NorthEast is a 500-bed, acute-care teaching hospital located in Concord, North Carolina, which serves as a primary percutaneous coronary intervention (PCI) center as well as a tertiary referral hospital for ST-elevation myocardial infarction. With more than 20 cardiologists/cardiac advanced care providers the cath labs perform approximately 2,000 catheterizations per year and 1,200 PCIs annually. Procedures include diagnostic left and right heart catheterizations, PCI, robotic PCI, rotational coronary atherectomy, intravascular ultrasound, fractional flow reserve, optical coherence tomography, hemodynamic support with Impella (Abiomed), intra-aortic balloon pump placement, pericardiocentesis as well as peripheral angiography and interventions including endovascular aneurysm repair in a hybrid room.

CHS-NE's robotic program began in 2013 with the 1st generation CorPath 200 System. The program has since evolved with an upgrade to the second generation CorPath GRX System. Dr. Campbell has been actively involved in the PRECISION registry and has published several articles relating to his work around stent savings with robotics, the use of the robotic system for precise measurement, and robotics for the reduction of staff radiation exposure.

The use of robotic coronary intervention was instituted to improve precision, accuracy, control and safety. The CorPath GRX System allows for successful complex robotic PCI with precise measurement, controlled device movements, constant fixation of devices, enhanced visualization, reduced radiation and improved ergonomics. Moreover, the addition of this innovative technology to our cath lab has increased the technical skills of the staff, improved staff morale and led to enhanced teamwork at CHS-NE.

manish

Dr. Manish A. Parikh, MD, FACC is the Associate Director of the Cardiac Catheterization Laboratory at the College of Physicians and Surgeons at Columbia University and the Director of Business Development at the Center for Interventional Vascular Therapy.

Dr. Parikh received his medical degree from UMDNJ in New Jersey and trained at The New York Hospital-Cornell University Medical Center in New York. Dr. Parikh specializes in complex coronary interventions and is a leader in medical education for the field.

NewYork-Presbyterian was one of nine clinical sites involved in the pivotal PRECISE Trial in 2011, which won the first generation CorPath 200 System FDA 510(k) clearance. The hospital then began performing robotic-assisted PCI regularly in 2012 with the CorPath 200 System. In early 2017, NYP was one of the first three hospitals to install and perform procedures using the second generation CorPath GRX System. Today, Dr. Parikh is the course proctor for Robotic Skills Labs taking place regularly in New York.

michael

Dr. Michael Ragosta is board certified in Internal Medicine, Cardiovascular diseases and Interventional cardiology. He specializes in Interventional Cardiology with an interest in complex coronary artery disease, chronic total occlusion and heart valve disease.

Dr. Ragosta has been principal investigator or co-principal investigator in numerous multicenter clinical trials involving coronary artery disease, coronary interventional therapy, valvular heart disease and coronary physiology. He has shared his research and experience through more than 40 invited lectures or visiting professorships and by authoring or co-authoring more than 120 peer-reviewed journal publications, books, book chapters and scientific abstracts. Dr. Ragosta is Medical Director for Interventional Cardiology at UVA.

UVA launched their robotic program in 2014 with the first generation CorPath 200 System. In 2017, UVA was one of the first three hospitals to install and perform procedures with the second generation CorPath GRX System.

kanwar

Dr. Kanwar Singh is board certified in Cardiovascular Disease and Interventional Cardiology. His research interests are centered on the evaluation and application of novel therapeutic devices and medical strategies employed in the Cath Lab. Dr. Singh received his medical degree from McGill University and trained at Brigham and Women's Hospital and Duke University.

UVA launched their robotic program in 2014 with the first generation CorPath 200 System. In 2017, UVA was one of the first three hospitals to install and perform procedures with the second generation CorPath GRX System.

frances

Dr. Frances Wood is a board certified interventional and structural cardiologist, specializing in complex coronary interventions and valvular disease. She is the Cardiology Director of Structural Heart at WakeMed. Dr. Wood received her medical degree from Eastern Virginia Medical School, completed her residency at University of Texas Southwestern Medical Center, and completed multiple fellowships at William Beaumont Hospital.

In additional to interventional training, she spent a focused year on structural cardiovascular services and brings expertise in advanced imaging and procedures such as: valve replacement (TAVR), mitral valve repair (MitraClip), atrial septal defect/patent foramen ovale closure, alcohol septal ablation, left atrial appendage occlusion, percutaneous balloon mitral valvuloplasty and paravalvular leak closure.

WakeMed launched their robotic program with the installation of three CorPath GRX Systems in May 2017. Dr. Wood is the Robotic Program Director for the hospital.